ASCO 2019 | Smart Start phase 2 trial: Rituximab, lenalidomide & ibrutinib combination for naive DLBCL

ASCO 2019: Results of a phase II study investigating the combination of lenalidomide, ibrutinib and rituximab for first line treatment of diffuse large b-cell lymphoma.